Abstract: A method of treating tinnitus in a subject is described that includes administering a therapeutically effective amount of a group II metabotropic glutamate receptor (mGluR) agonist to the subject. A method of screening a subject having tinnitus for treatment with a group II mGluR agonist that includes testing the use of residual inhibition to suppress tinnitus in the subject, wherein suppression of tinnitus by residual inhibition indicates that a group II mGluR agonist would be effective for treating tinnitus in the subject, is also described.

Abstract: Provided herein are methods to promote tissue healing, to treat tissue injury or to treat a condition related to tissue injury comprising administering to a subject in need thereof an effective amount of one or both of: a CAMKK1 polypeptide or an equivalent thereof; or an SDF-1 polypeptide or an equivalent thereof, in the presence of CXCR4 polypeptide expression, wherein the effective amount is an amount that induces exosome production, secretion and/or function in the subject. Recombinant stem cells are also provided that overexpress one or both of a CAMKK1 protein or polypeptide and/or an SDF-1 protein or polypeptides. The stem cells and products produced from them are useful to treat ischemic or inflammatory conditions as well as to promote tissue healing.

Abstract: A method for treating or preventing heart failure involving blockage of small blood vessels is described. The method involves administering to a subject in need thereof a therapeutically effective amount of a vasodilator.

Abstract: A method for treating a skin wound of a subject is described. The method includes contacting the skin wound with a therapeutically effective amount of a wound healing composition comprising glycoprotein nonmelanoma clone B (GPNMB) protein, an active peptide fragment thereof, a GPNMB analog, a GPNMB potentiating agent, or a combination thereof.

Abstract: Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.

Abstract: A method for treating or preventing heart failure involving blockage of small blood vessels is described. The method involves administering to a subject in need thereof a therapeutically effective amount of a vasodilator.

Abstract: A method of treating tinnitus in a subject is described that includes administering a therapeutically effective amount of a group II metabotropic glutamate receptor (mGluR) agonist to the subject. A method of screening a subject having tinnitus for treatment with a group II mGluR agonist that includes testing the use of residual inhibition to suppress tinnitus in the subject, wherein suppression of tinnitus by residual inhibition indicates that a group II mGluR agonist would be effective for treating tinnitus in the subject, is also described.

Abstract: Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.

Abstract: Methods useful for treating ischemic heart disease, reducing cardiac fibrosis, improving cardiac function, or increasing coronary angiogenesis are described.

Abstract: A composition for enhancing bone tissue repair or regeneration is described. The composition includes osteoactivin or an active peptide fragment thereof and a biocompatible material. Osteogenic orthopedic devices including the osteoactivin-containing composition are also described. The devices and compositions can be used in methods for enhancing bone tissue repair or regeneration by contacting a site in need of bone repair or regeneration in a subject with the osteoactivin-containing composition.

Abstract: Provided herein are methods to promote tissue healing, to treat tissue injury or to treat a condition related to tissue injury comprising administering to a subject in need thereof an effective amount of one or both of: a CAMKK1 polypeptide or an equivalent thereof; or an SDF-1 polypeptide or an equivalent thereof, in the presence of CXCR4 polypeptide expression, wherein the effective amount is an amount that induces exosome production, secretion and/or function in the subject. Recombinant stem cells are also provided that overexpress one or both of a CAMKK1 protein or polypeptide and/or an SDF-1 protein or polypeptides. The stem cells and products produced from them are useful to treat ischemic or inflammatory conditions as well as to promote tissue healing.

Abstract: Methods useful for treating ischemic heart disease, reducing cardiac fibrosis, improving cardiac function, or increasing coronary angiogenesis are described.

Abstract: In an aspect of the present application, compositions and methods are provided for preventing bone loss and/or stimulating bone healing in a subject in need thereof. Compositions can comprise a pharmaceutically acceptable carrier and a therapeutically effective amount of a zinc-finger CCHC domain-containing protein 6 (ZCCHC6) inhibitor. Methods can include administering a therapeutically effective amount of the ZCCHC6 inhibitor to the subject.

Abstract: A method for treating a skin wound of a subject is described. The method includes contacting the skin wound with a therapeutically effective amount of a wound healing composition comprising glycoprotein nonmelanoma clone B (GPNMB) protein, an active peptide fragment thereof, a GPNMB analog, a GPNMB potentiating agent, or a combination thereof.

Abstract: Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.

Abstract: Methods for synthesizing amooranin (25-hydroxy-3-oxoolean-12-en-28-oic acid (AMR) and/or amooranin analogs, including amooranin methyl ester (AMR-Me), by using oleanolic acid in an oxidation process, and therapeutic uses thereof are described.

Abstract: Embodiments of the invention provide a method of improving the efficacy of an anti-cancer therapy and a method of treatment of cancer by normalizing angiogenesis in cancer. By enhancing the cell signaling pathway via a TRPV4 receptor in tumor endothelial cells, either by a TRPV4 agonist or by increasing the expression of TRPV4 in the tumor endothelial cells, the tumor endothelial cells behave normally and form normal angiogenic network for better anti-cancer therapy to the tumors.